Spots Global Cancer Trial Database for advanced liver cancer
Every month we try and update this database with for advanced liver cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma | NCT05603039 | Advanced Liver ... | QL1706 QL1604 Bevacizumab | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| Camrelizumab Utilization on Patients With Advanced Liver Cancer | NCT04487704 | Advanced Hepato... | camrelizumab | 18 Years - | First Affiliated Hospital Xi'an Jiaotong University | |
| Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC | NCT03412773 | Hepatocellular ... | Tislelizumab Sorafenib | 18 Years - | BeiGene | |
| A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma | NCT05603039 | Advanced Liver ... | QL1706 QL1604 Bevacizumab | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer | NCT04163237 | Advanced Liver ... | PD-1 Sorafenib | - | Guangxi Medical University | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| Plasmodium Immunotherapy for Breast and Liver Cancers | NCT03474822 | Advanced Breast... Advanced Liver ... | Blood-stage inf... | 18 Years - 70 Years | CAS Lamvac Biotech Co., Ltd. | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer | NCT03484962 | Advanced Liver ... | Activated CIK a... cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma | NCT05603039 | Advanced Liver ... | QL1706 QL1604 Bevacizumab | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer | NCT04163237 | Advanced Liver ... | PD-1 Sorafenib | - | Guangxi Medical University | |
| Study of BGB-A317 in Participants With Previously Treated Unresectable HCC | NCT03419897 | Hepatocellular ... | Tislelizumab | 18 Years - | BeiGene | |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor | NCT04906434 | Advanced Liver ... | 60mg ABSK-011ca... 120mg ABSK-011c... 180mg ABSK-011c... 240mg ABSK-011c... 320 mg ABSK-011... 400mg ABSK-011c... | 18 Years - 75 Years | Abbisko Therapeutics Co, Ltd | |
| STA-9090 in Patients With Advanced Hepatocellular Cancer | NCT01665937 | Hepatocellular ... | STA-9090 | 18 Years - | Massachusetts General Hospital | |
| Camrelizumab Utilization on Patients With Advanced Liver Cancer | NCT04487704 | Advanced Hepato... | camrelizumab | 18 Years - | First Affiliated Hospital Xi'an Jiaotong University | |
| Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy | NCT01180959 | Liver Cancer | Bevacizumab Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer | NCT03484962 | Advanced Liver ... | Activated CIK a... cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients With Advanced Liver Cancer | NCT05698459 | Advanced Liver ... | OH2 injection | 18 Years - 75 Years | Binhui Biopharmaceutical Co., Ltd. | |
| Plasmodium Immunotherapy for Breast and Liver Cancers | NCT03474822 | Advanced Breast... Advanced Liver ... | Blood-stage inf... | 18 Years - 70 Years | CAS Lamvac Biotech Co., Ltd. | |
| Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer | NCT02862613 | Precision Cells Transcatheter A... Advanced Liver ... | TACE Precision Cells | 18 Years - 65 Years | Shanghai International Medical Center | |
| Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer | NCT02873442 | Precision Cell ... Transcatheter A... Advanced Liver ... | TACE Precision Cells | 18 Years - 65 Years | Ningbo Cancer Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
